Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

NCT03130348 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was dropped at site before participation

Conditions

Amyloidosis
Immunoglobulin Light Chain Deposition

Interventions

DRUG: Bortezomib
DRUG: Dexamethasone
DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

Mayo Clinic

Collaborators

[object Object]